CTOs on the Move


 
Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.trevenainc.com
  • 1018 W 8th Ave Ste A
    King Of Prussia, PA USA 19406
  • Phone: 610.354.8840

Executives

Name Title Contact Details

Similar Companies

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

Custom Biogenic Systems

Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iterion Therapeutics

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.

PreciThera

PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.